CRISPR Therapeutics AG (CRSP) Company Overview

What does CRISPR Therapeutics do?

CRISPR Therapeutics AG is a Swiss-incorporated biopharmaceutical company listed on the Nasdaq Global Market under CRSP. It applies gene editing to create medicines intended to make durable changes to disease biology rather than repeatedly manage symptoms. The company’s official investor information identifies Zug, Switzerland as its headquarters and confirms an October 2016 initial public offering.

Which disease areas define the portfolio?

The portfolio combines ex vivo editing, where cells are modified outside the body and reinfused, with in vivo editing delivered directly to target tissues. The company’s official pipeline spans sickle cell disease and transfusion-dependent beta thalassemia, cardiovascular and rare liver diseases, autoimmune disease, oncology and type 1 diabetes. This breadth matters because the business is no longer a single-asset research story, but most programs remain investigational.

Why does the company matter?

Its importance comes from clinical validation. CASGEVY moved CRISPR science through global trials, manufacturing, regulatory review and launch. The November 2023 United Kingdom authorization was the first regulatory authorization of a CRISPR-based therapy worldwide. That milestone reduces platform skepticism without removing clinical, safety, access or manufacturing risk.

How does CRISPR Therapeutics make money?

The model has three layers: CASGEVY profit sharing, collaboration or licensing payments, and future wholly owned products. CRISPR Therapeutics has no wholly owned product sales, and Q1 2026 recognized revenue was not material.

Why is CASGEVY revenue different from CRSP reported revenue?

CASGEVY generated $116 million of commercial revenue in FY2025 and $43 million in Q1 2026, but those are collaboration-product sales, not CRSP GAAP product revenue. Vertex is manufacturer and exclusive license holder. CRSP records its share of program costs and profits within collaboration expense, net, which declined to $45.9 million in Q1 2026 from $57.5 million a year earlier as higher sales offset more program cost.

What is the central strategic trade-off?

Partnering lowers execution burden but caps CASGEVY economics at 40%. Wholly owned programs preserve more upside while increasing burn. Analysis should separate validated collaboration economics from earlier pipeline optionality.

Which pipeline programs matter most?

The pipeline combines different technical and commercial bets. CASGEVY is approved but operationally complex. In vivo liver editing targets larger populations, while zugo-cel tests an off-the-shelf CAR-T model. Regenerative medicine and SyNTase are earlier-stage extensions.

How should researchers rank the programs?

What pipeline metrics matter most?

For CASGEVY, watch collections, infusions, reimbursement and collaboration expense. For in vivo assets, dose response, durability, liver safety and later-stage progression matter. For zugo-cel, response durability, cell expansion, safety and manufacturing consistency are decisive.

What turning points created today’s CRISPR Therapeutics?

Each turning point changed platform translation, funding or the balance between partnered and wholly owned value.

1. 2013-2014
   The Swiss company was incorporated and adopted the CRISPR Therapeutics name, establishing an enterprise around foundational CRISPR/Cas9 intellectual property and scientific leadership.
2. 2015
   The Vertex collaboration began, supplying disease expertise, capital and a commercial pathway for hemoglobinopathies while sharing eventual economics.
3. 2016
   The Nasdaq IPO created public-market funding access; the offering priced at $14 per share and supported a multi-program development strategy.
4. 2018
   The company advanced the first CRISPR/Cas9 gene-edited therapy into the clinic for SCD and TDT, moving the platform from preclinical promise to human validation.
5. 2021
   The CASGEVY arrangement was amended so Vertex would lead global development, manufacturing and commercialization under a 60/40 cost-and-profit split.
6. 2023
   CASGEVY received the world’s first CRISPR-therapy authorization, changing CRSP from a development-only company into a participant in commercial medicine economics.
7. 2025-2026
   The company expanded into siRNA through Sirius, advanced in vivo and autoimmune programs, and raised $600 million of convertible notes to extend strategic flexibility.

What does the history imply now?

CRISPR Therapeutics has already cleared the field’s first major regulatory hurdle, but its next phase is harder to evaluate: it must turn one partnered success into a repeatable platform. The 2015 Vertex decision created credibility and launch capability; current capital allocation is designed to preserve enough resources to prove additional franchises without depending on immediate CASGEVY cash generation.

What does CRISPR Therapeutics’ latest quarter show?

The latest official period is the quarter ended March 31, 2026. The Q1 2026 Form 10-Q shows minimal GAAP revenue, lower year-over-year operating expenses, substantial cash use and greater post-financing liquidity.

Where did the spending go?

What does the annual baseline add?

The FY2025 results reported $3.5 million of revenue, $284.8 million of R&D, $96.3 million of acquired in-process R&D, $213.5 million of collaboration expense and a $581.6 million net loss. CASGEVY generated $116 million of revenue, with 64 infusions and 147 first collections. Commercial adoption is improving, but the balance sheet still funds the company.

How financially strong is CRISPR Therapeutics?

Financial strength is the clearest near-term asset. At March 31, 2026, cash and marketable securities totaled $2.44 billion versus $1.98 billion at year-end 2025, largely after a $600 million convertible-note issue that produced about $585.2 million of net proceeds.

What did the convertible-note financing change?

The financing details are documented in the March 2026 Form 8-K. The notes carry an effective 1.125% coupon for investors, increased to a stated 1.7308% to address anticipated Swiss withholding mechanics.

How long can the balance sheet support development?

A static run-rate comparison suggests flexibility, not a guaranteed runway. Q1 2026 operating cash use of $108.9 million annualizes to roughly $436 million, implying more than five years against $2.44 billion of liquidity. Burn may rise with larger trials, making cash use per clinical milestone the better monitor.

Who are CRISPR Therapeutics’ main competitors?

Competition operates at several levels: editing technology, therapeutic modality, target disease and commercialization infrastructure. The company’s 2025 Form 10-K identifies direct CRISPR competitors such as Intellia Therapeutics and Editas Medicine, next-generation editing developers including Beam Therapeutics and Prime Medicine, and companies using TALEN, meganuclease or zinc-finger approaches.

Is CRISPR Therapeutics a market leader?

It is a leader in clinical and regulatory execution because CASGEVY established first-mover validation. That is different from having a durable monopoly. Gene-editing patents are complex, alternative technologies are advancing, and therapeutic markets are indication-specific. Leadership is best measured by approved products, quality of human data, delivery capability, manufacturing reproducibility and the speed at which capital is converted into meaningful clinical milestones.

What gives CRISPR Therapeutics a competitive advantage?

Its strongest resources are experience taking a CRISPR program to approval, Vertex collaboration infrastructure, IP and know-how, proprietary platforms, internal cell-therapy manufacturing and substantial liquidity. These create an advantage, but the moat remains probabilistic because value depends on future trial results.

Which advantages are most durable?

Execution knowledge and accumulated clinical data are more durable than a first-mover headline. Delivery is particularly important: successful liver LNP delivery, targeted conditioning or immune-evasive cell engineering could create reusable capabilities across multiple assets. The internal Framingham GMP facility can improve control over zugo-cel development and future supply. Yet each capability must demonstrate repeatability; a platform claim becomes a moat only when multiple programs show favorable safety, efficacy and manufacturability.

Who owns CRSP stock, and how is the company governed?

CRISPR Therapeutics has one listed common-share class rather than a founder-controlled dual-class structure. The 2026 proxy statement reports 96,385,506 common shares outstanding at March 31, 2026 and identifies three holders above 5%.

What does the ownership profile signal?

Board governance uses Audit, Compensation and Nominating committees with members identified as independent under Nasdaq standards. Shareholders supported the 2025 U.S. say-on-pay proposal with approximately 71% of votes cast, a majority but also a signal that compensation design attracted material dissent. For investors, governance is therefore institutionally influenced rather than founder-controlled.

Which opportunities and risks could change the story?

The largest opportunity is platform replication through in vivo editing or scalable allogeneic CAR-T. The largest risk is that breadth becomes expensive optionality without enough late-stage evidence. Filings emphasize clinical, safety, manufacturing, commercialization, IP, collaborator and financing risks.

Where is the risk-reward asymmetry?

A successful common-disease in vivo program could support multiple liver targets. A target-specific failure may be contained, while a delivery or class-safety issue could impair several assets. Zugo-cel offers centralized manufacturing and inventory advantages, but durability must justify lymphodepletion and treatment complexity.

Why does CRISPR Therapeutics matter for valuation?

A revenue multiple is incomplete because reported revenue excludes CASGEVY product sales and most pipeline value is pre-revenue. A DCF or sum-of-the-parts model should separate cash, debt, CASGEVY economics and each program by probability, timing, pricing, margins and reinvestment.

Which DCF drivers are most sensitive?

For comparables, pipeline stage, cash-adjusted enterprise value, validated modalities, partnership quality and catalysts matter more than current revenue. The central question is how efficiently capital becomes de-risked assets.

What is the key takeaway from CRISPR Therapeutics analysis?

CRISPR Therapeutics occupies a rare position: it has participated in the first approved CRISPR medicine while retaining enough capital and platform breadth to pursue several second acts. CASGEVY validates the science and creates a growing 40% economic interest, but launch complexity means commercial value will build through treatment-center capacity, reimbursement, cell collections and infusions rather than a simple prescription curve.

The company’s strongest support is its $2.44 billion Q1 2026 liquidity base, clinical-development experience, Vertex partnership, internal manufacturing and diversified in vivo, CAR-T, regenerative and SyNTase programs. The main weakness is that CRSP remains deeply loss-making, with $122.9 million of Q1 net loss and $108.9 million of operating cash use. Much of the valuation therefore rests on uncertain future assets rather than current earnings.